Novavax Inc
General ticker "NVAX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.4B
Novavax Inc follows the US Stock Market performance with the rate: 34.1%.
Estimated limits based on current volatility of 2.3%: low 8.43$, high 8.80$
Factors to consider:
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.60$, 10.48$]
- 2024-12-30 to 2025-12-30 estimated range: [4.86$, 12.59$]
Financial Metrics affecting the NVAX estimates:
- Negative: Non-GAAP EPS, $ of -5.53 <= 0.10
- Negative: Operating profit margin, % of -36.54 <= 1.03
- Negative: Operating cash flow per share per price, % of -56.72 <= 2.35
- Negative: negative Net income
- Positive: -0.96 < Investing cash flow per share, $ of -0.58
- Positive: Interest expense per share, $ of 0.14 <= 0.74
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term NVAX quotes
Long-term NVAX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1,146.29MM | $1,981.87MM | $983.71MM |
| Operating Expenses | $2,832.87MM | $2,626.61MM | $1,550.22MM |
| Operating Income | $-1,686.58MM | $-644.74MM | $-566.51MM |
| Non-Operating Income | $-27.96MM | $-8.91MM | $23.48MM |
| Interest Expense | $21.13MM | $19.88MM | $14.42MM |
| R&D Expense | $2,534.51MM | $1,235.28MM | $737.50MM |
| Income(Loss) | $-1,714.54MM | $-653.65MM | $-543.03MM |
| Taxes | $29.21MM | $4.29MM | $2.03MM |
| Profit(Loss) | $-1,743.75MM | $-657.94MM | $-545.06MM |
| Stockholders Equity | $-351.67MM | $-634.08MM | $-716.93MM |
| Inventory | $1,956.97MM | $36.68MM | $41.70MM |
| Assets | $2,576.75MM | $2,258.68MM | $1,797.49MM |
| Operating Cash Flow | $322.95MM | $-415.94MM | $-713.97MM |
| Capital expenditure | $57.49MM | $92.98MM | $58.81MM |
| Investing Cash Flow | $100.15MM | $-92.98MM | $-58.81MM |
| Financing Cash Flow | $461.71MM | $324.99MM | $4.47MM |
| Earnings Per Share* | $-23.44 | $-8.42 | $-5.41 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.